

Editor's Comment:

The authors should explain patients still using imatinib even they had criteria to change to second line therapy (leukemianet). Why this patients were still using imatinib after 1 year of treatment?

The conclusion is wrong. It shall not mention progression, prognosis and survival as it was not analysed at the paper (short follow-up). Longer follow- up is needed to reach this conclusions

Editor's Details:

Dr. Talita Maira Bueno Da Silveira Da Rocha
Hematology and Oncology, Santa Casa Medical School, Brazil